vs
Side-by-side financial comparison of bioAffinity Technologies, Inc. (BIAF) and SOCIETY PASS INCORPORATED. (SOPA). Click either name above to swap in a different company.
bioAffinity Technologies, Inc. is the larger business by last-quarter revenue ($1.6M vs $1.4M, roughly 1.2× SOCIETY PASS INCORPORATED.). bioAffinity Technologies, Inc. runs the higher net margin — -197.0% vs -370.8%, a 173.9% gap on every dollar of revenue. On growth, SOCIETY PASS INCORPORATED. posted the faster year-over-year revenue change (-17.6% vs -27.8%). bioAffinity Technologies, Inc. produced more free cash flow last quarter ($-2.6M vs $-16.7M). Over the past eight quarters, SOCIETY PASS INCORPORATED.'s revenue compounded faster (-11.2% CAGR vs -18.6%).
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
The Wilderness Society is an Australian, community-based, not-for-profit non-governmental environmental advocacy organisation.
BIAF vs SOPA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $1.4M |
| Net Profit | $-3.1M | $-5.1M |
| Gross Margin | — | 64.3% |
| Operating Margin | -196.9% | -379.9% |
| Net Margin | -197.0% | -370.8% |
| Revenue YoY | -27.8% | -17.6% |
| Net Profit YoY | -5.7% | -271.5% |
| EPS (diluted) | $-3.59 | $-0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | — | ||
| Q3 25 | $1.4M | $1.4M | ||
| Q2 25 | $1.3M | $2.5M | ||
| Q1 25 | $1.9M | $1.5M | ||
| Q4 24 | $2.2M | $1.9M | ||
| Q3 24 | $2.4M | $1.7M | ||
| Q2 24 | $2.4M | $1.7M | ||
| Q1 24 | $2.4M | $1.8M |
| Q4 25 | $-3.1M | — | ||
| Q3 25 | $-5.1M | $-5.1M | ||
| Q2 25 | $-4.1M | $479.0K | ||
| Q1 25 | $-2.7M | $-1.8M | ||
| Q4 24 | $-3.0M | $-4.1M | ||
| Q3 24 | $-2.0M | $-1.4M | ||
| Q2 24 | $-2.1M | $-1.9M | ||
| Q1 24 | $-2.0M | $-2.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 64.3% | ||
| Q2 25 | — | 56.5% | ||
| Q1 25 | — | 31.6% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | 27.1% | ||
| Q1 24 | — | 26.7% |
| Q4 25 | -196.9% | — | ||
| Q3 25 | -158.6% | -379.9% | ||
| Q2 25 | -198.2% | -6.1% | ||
| Q1 25 | -141.7% | -126.6% | ||
| Q4 24 | -133.5% | -165.6% | ||
| Q3 24 | -84.0% | -70.1% | ||
| Q2 24 | -87.1% | -126.0% | ||
| Q1 24 | -80.8% | -156.6% |
| Q4 25 | -197.0% | — | ||
| Q3 25 | -349.3% | -370.8% | ||
| Q2 25 | -319.9% | 19.1% | ||
| Q1 25 | -143.5% | -124.9% | ||
| Q4 24 | -134.4% | -217.5% | ||
| Q3 24 | -85.1% | -82.2% | ||
| Q2 24 | -88.0% | -113.3% | ||
| Q1 24 | -81.5% | -153.8% |
| Q4 25 | $-3.59 | — | ||
| Q3 25 | $-4.74 | $-0.89 | ||
| Q2 25 | $-0.17 | $0.10 | ||
| Q1 25 | $-0.16 | $-0.44 | ||
| Q4 24 | $-17.27 | $-1.03 | ||
| Q3 24 | $-4.84 | $-0.48 | ||
| Q2 24 | $-0.19 | $-0.73 | ||
| Q1 24 | $-0.20 | $-1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3M | $13.9M |
| Total Assets | $11.0M | $32.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | — | ||
| Q3 25 | $7.7M | $6.6M | ||
| Q2 25 | $802.8K | $8.2M | ||
| Q1 25 | $444.7K | $7.1M | ||
| Q4 24 | $1.1M | $7.6M | ||
| Q3 24 | $756.6K | $4.2M | ||
| Q2 24 | $801.3K | $833.9K | ||
| Q1 24 | $2.5M | $1.6M |
| Q4 25 | $7.3M | — | ||
| Q3 25 | $8.9M | $13.9M | ||
| Q2 25 | $-2.1M | $2.4M | ||
| Q1 25 | $1.4M | $-663.0K | ||
| Q4 24 | $2.6M | $-2.1M | ||
| Q3 24 | $3.1M | $862.6K | ||
| Q2 24 | $3.4M | $2.4M | ||
| Q1 24 | $5.3M | $3.5M |
| Q4 25 | $11.0M | — | ||
| Q3 25 | $11.5M | $32.9M | ||
| Q2 25 | $4.8M | $29.2M | ||
| Q1 25 | $5.5M | $22.9M | ||
| Q4 24 | $6.5M | $21.3M | ||
| Q3 24 | $6.6M | $17.0M | ||
| Q2 24 | $6.7M | $13.0M | ||
| Q1 24 | $8.0M | $13.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $-16.7M |
| Free Cash FlowOCF − Capex | $-2.6M | $-16.7M |
| FCF MarginFCF / Revenue | -160.7% | -1211.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-2.5M | $-16.7M | ||
| Q2 25 | $-2.6M | $-1.8M | ||
| Q1 25 | $-1.6M | $-4.0M | ||
| Q4 24 | $-1.7M | $3.7M | ||
| Q3 24 | $-1.7M | $2.0M | ||
| Q2 24 | $-1.5M | $-864.6K | ||
| Q1 24 | $-2.3M | $-2.4M |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-2.5M | $-16.7M | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.4M | — |
| Q4 25 | -160.7% | — | ||
| Q3 25 | -171.8% | -1211.0% | ||
| Q2 25 | -209.6% | — | ||
| Q1 25 | -91.3% | — | ||
| Q4 24 | -76.0% | — | ||
| Q3 24 | -73.1% | — | ||
| Q2 24 | -65.1% | — | ||
| Q1 24 | -99.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.7% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -3.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
